
Cancer cells use nutrients like glucose and glutamine to make energy and build the materials they need to grow. That’s why researchers have looked at whether two antiparasitic drugs, fenbendazole and mebendazole, can interfere with how tumor cells use those fuels. In a 2018 *Scientific Reports* study, fenbendazole reduced glucose uptake and lactate production in two human lung cancer cell lines. It also reduced the activity of hexokinase II, the enzyme that kicks off glycolysis by trapping glucose inside the cell in a form it can use. The researchers also observed signs of programmed cell death through a pathway involving the mitochondria. Mebendazole affected a different part of the picture. In a 2023 study, lab-grown gastric cancer cells took up less glucose and produced less ATP, the molecule cells use to power their activities. In a separate glioma study, glutamine accumulated inside treated cells while glutamate and succinate fell. That pattern suggests the cells were breaking down less glutamine, which can feed energy production in the mitochondria. The researchers proposed that this could reduce mitochondrial ATP production.
















